Founded in 2015, VitaDX develops and markets cancer diagnostic solutions that combine image analysis and artificial intelligence in cytology, using its patented VisioCyt® technology.
Our mission is to develop innovative, high-performance solutions that can make a meaningful difference to healthcare systems and improve care for as many patients as possible.
Following several years of development and a prospective multicentre clinical study, VitaDX’s first solution, VisioCyt® Bladder, is CE marked under the IVDR. Using a simple urine sample, it supports the diagnosis and surveillance of bladder cancer. Other solutions are currently in development, including for bladder cancer screening and thyroid cancer diagnosis.
Innovation is at the heart of everything we do. We challenge established conventions, explore new approaches and continually invest in research and development to remain at the forefront of technology and overcome complex technical challenges.
We are committed to making our technologies accessible to as many patients as possible. We also foster an open and collaborative culture that encourages initiative and individual responsibility, recognising every team member’s contribution to our shared success.
We are driven by the positive impact we can have on patients’ lives and strive to develop solutions that improve their wellbeing. We value people beyond their roles as patients or professionals, bringing our strengths together around a shared purpose. More than a team, we are a true community.
